The role of heparan sulphate in pathogenesis of Crimean-Congo hemorrhagic fever disease by Fatma Mutlu Kukul Guven et al.
INTRODUCTION
Crimean-Congo hemorrhagic fever (CCHF) is an
infectious disease caused by Nairovirus genus from
Bunyaviridae family. It begins with fever, severe head-
ache, weakness, nausea, vomiting and progresses with
bleeding in different parts of the body. The bleeding find-
ings emerge as subcutaneous bleeding, nasal bleeding,
gingival bleeding and visceral bleeding1.
CCHF virus is known to be infected by mononuclear
phagocytic cells, liver cells and endothelial cells; how-
ever, its pathogenesis is not fully clarified2–4. The dis-
ease courses subclinically in some cases, while may re-
sult in mortality in other cases with developing shock and
disseminated intravascular coagulopathy (DIC). Although
genetic strains similar to CCHF have been detected in
Turkey5, the cause of the clinical differences between the
cases is not known.
Heparan sulphate (HS) is a proteoglycan synthesized
in the endothelial cells and found in the extracellular part
of the plasma membrane. HS interacts with growth fac-
J Vector Borne Dis 50, June 2013, pp. 133–136
The role of heparan sulphate in pathogenesis of Crimean-Congo
hemorrhagic fever disease
Fatma Mutlu Kukul Guven
1, Hüseyin Aydin
2, Ali Kaya
3, Aynur Engin
4, V. Kenan Celik
2,
Ilhan Korkmaz
1, Bahri Atli
5 & Dilara Icagasioglu
3
1Department of Emergency Medicine; 2Department of Biochemistry; 3Department of Pediatrics; 4Department of Infectious Disease and
Clinical Microbiology Medicine, Cumhuriyet University School of Medicine, Swas; 5Emergency Service, Karabuk State Hospital, Karabuk,
Turkey
ABSTRACT
Background & objectives: Crimean-Congo hemorrhagic fever (CCHF) is a viral infection typically transmitted
by tick bite. This study is to define the level of heparan sulphate (HS) in serum/urine since HS may play a role in
the pathogenesis of hemorrhagic events in the patients with CCHF.
Methods: In this study, the patient group consisted of 79 cases with a positive diagnosis of CCHF according to
PCR/ELISA outcome among the patients referred to Cumhuriyet University, School of Medicine in 2010. A total
of 81 volunteers who had not any viral or metabolic disease were enrolled as the control group. The blood samples
were centrifuged, and the serum and urine samples obtained were stored at –80°C until they were studied. Then,
these samples were simultaneously dissolved, and HS level was spectrophotometrically measured using
glycosaminoglycans specific 1–9, dimethyl-methylene blue (DMMB) stain.
Results: A statistically significant increase in the HSserum values was found both in the individuals under and
above 16 yr old in the patient groups compared to the controls (p <0.05). Also there was a statistically significant
increase in the urine levels of HS in the cases >16 yr old compared to the controls (p <0.05).
Interpretations & conclusion: Increase of the serum/urine levels of HS was though to be due to vascular endothelium
damage and to liver injury as well as vascular endothelium damage in the patients who died. Further, comprehensive
studies are needed to demonstrate whether the serum/urine levels of HS are correlated to liver and vascular
endothelium damage and prognosis of the disease.
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tors such as sulphate basic fibroblast growth factor
(bFGF), collagen, laminin and fibronectin better supports
the integrity of the vessels6. HS is considered as the ini-
tial receptor for numerous viruses. A number of envel-
oped viruses bind to HS, while few number of the bound
non-enveloped viruses is limited7. In this study, serum/
urine levels of HS in the infected patients with CCHF
that is an enveloped virus were studied and its impacts on
the hemorrhagic events were investigated.
MATERIAL & METHODS
In this study, serum samples are taken from the pa-
tients referred to the Cumhuriyet University School of
Medicine, Department of Emergency Medicine, Depart-
ment of Infectious Diseases, Department of Clinical Mi-
crobiology, and the Department of Pediatrics with a tick
bite history/pre-diagnosis of CCHF in 2010. Of these
samples, 79 cases with a positive diagnosis of CCHF ac-
cording to the PCR/ELISA results from Refik Saydam
Institute of Public Health were selected for the study. Age J Vector Borne Dis 50, June 2013 134
and gender matched, 81 volunteers who had not any viral
or metabolic disease were enrolled as the control group.
The serum samples of both the groups were centrifuged
at 4000 rpm for 5 min using Hettich Universal 30 centri-
fuge device. The serum and urine samples were stored at
–80°C until the study was carried out. All the samples
were simultaneously dissolved, and HS level was spec-
trophotometrically measured using glycosaminoglycans
specific 1–9, dimethyl-methylene blue stain and standard8.
This study was conducted by the approval of
Cumhuriyet University School of Medicine Ethics Com-
mittee. Informed consent was obtained from the patients
and healthy volunteers.
Statistical analysis
Data obtained from the study were entered to the SPSS
15.0 software. Data were analysed using chi-square,
t-test for two independent variables; and Pearson’s corre-
lation test and receiver operating characteristic (ROC)
analysis. Appropriate values of p <0.05 were considered
statistically significant. All the variables were expressed
as mean ± standard deviation.
RESULTS
A total of 79 CCHF patients and 81 volunteer indi-
viduals were enrolled to this study. The differences be-
tween the controls and patient groups in terms of age and
gender were not found statistically significant (p >0.05).
Demographic features of the controls and patient groups
are given in Table 1.
A statistically significant increase was observed in
the levels of HSserum in the persons under and >16 yr-old
both in the patients according to control groups (p <0.05)
(Table 2). Urine levels of HS could not be evaluated in
those <16 yr-old since the samples could not be collected.
However, levels of HSurine were found statistically sig-
nificant higher in those >16 yr-old than in the controls
(p <0.05) (Table 2).
CCHF patients under the age of 16 yr could not be
included for Swanepoel criteria and ROC analysis due to
information of the patients could not be attained. Accord-
ing to Swanepoel et al9 criteria, 26 patients were defined
as severe. These patients had hemorrhagic events. The
types of hemorrhagic events were mostly epistaxis, vagi-
nal bleeding and gastrointestinal bleeding, gingival bleed-
ing, petechiae, and hematomas in different parts of the
body. ROC analysis was performed for calculating the
cut-off value in patients with bleeding for HSserum. The
size of the area under the curve was found to be 0.662
(p = 0.047, p <0.05). This area of 95% confidence limits
was found to be 0.514 to 0.813. Accordingly, in patients
with bleeding, the cut-off value of HSserum was obtained
as 13.25. The sensitivity value for this point was found as
0.769, the specificity value 0.526. ROC analysis related
to this subject in shown is Fig. 1.
Table 2. Levels of heparan sulphate in the patient and control group
Measurements  Control Patient P
<16 yr n = 30 n = 28
HSserum (mg/mL) 10.30 ± 2.72 20.34 ± 7.57 0
>16 yr n = 51 n = 51
HSserum(mg/mL) 12.48 ± 3.24 18.55 ± 8.07 0
HSurine(mg/mL)  3.72 ± 1.08  8.69 ± 3.49 0
 Table 1. Demographic characteristics of the patients
Age (yr ) Male (%) Female (%)
<16 yr
Control (n=30) 10.20 ± 4.44 23 (76.7) 7 (23.3)
Patient (n=28) 10.14 ± 4.03 22 (78.6) 6 (21.4)
>16 yr
Control (n=51) 47.22 ± 15.63 29 (56.9) 22 (43.1)
Patient (n=51) 50.11 ± 16.55 28 (54.9) 23 (45.1)
Fig. 1: ROC analysis for cut-off value of HSserum in patients with
bleeding.
In living patients, between ALT, AST and HSserum
negative way, a correlation coefficient was found. This
correlation coefficient is statistically insignificant and very
small. In the patients who died, between HSserum with in-
ternational normalised ratio (INR), ALT, AST, ALP and
LDH was found with a statistically insignificant positive
correlation. Between ALT, AST and LDH moderate cor-
relations were found. The reason why the correlation in-
significant can be explained by the low number of sub-
jects. The comparison of level of HS with liver enzymes
and INR in the group of patients and controls is shown in
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DISCUSSION
In this study, a statistically significant increase de-
fined in the serum/urine levels of HS in the patients with
CCHF compared to the control group was found. HS is
widely found on the cell surfaces and extracellular ma-
trix of the mammals. This contributes to many biological
processes such as blood coagulation, viral infections,
embryonic development, wound healing and suppression
of tumor growth 10–15. HS causes tumor metastasis in the
organs such as liver, kidney and spleen by interaction with
cancer cells, platelets and endothelial cells16, 17.
HS binds to many ligands and microorganisms such
as growth factors, cytokines and chemokines. Binding to
HS on the cell surface have a critical importance for many
viruses to enter the cell10. HS synthesized in the endothe-
lial cells is found in the extracellular part of the plasma
membrane and helps to preserve the integrity of the ves-
sels. It is one of the most common glycosaminoglycans
found in the vascular endothelium. It is normally found
in the blood with a very low amount. HS has an antico-
agulant effect like heparin, by inhibiting antithrombin-
III (AT III)7, 12, 18, 19. Endogenous HS stimulates heparin
AT III, which is similar to itself in structure to inhibit the
occurrence of thrombin20. Therefore, increase of the se-
rum levels of HS associted with various factors leads to
bleeding.
CCHF is a zoonotic character infection which affects
many organs and systems, characterized by bleeding and
liver function abnormalities and takes place among the
viral hemorrhagic fever syndromes21.The pathogenesis of
viral hemorrhagic fevers shows similarity22, 23. Thus, un-
derstanding of the pathogenesis is important in planning
of the treatment. Although pathophysiology may differ
for each factor of the viral hemorrhagic fever, major com-
mon features such as microvascular disease and disrup-
tion of hemostasis come to the forefront23, 24.
Capillary endothelium is directly or indirectly targeted
in CCHF disease as with all viral hemorrhagic fevers.
CCHF virus mainly activates mononuclear cells and leads
to release of various cytokines and chemokines. These
chemokines indirectly target the endothelium. Further-
more, the destruction occurs also as a result of the direct
infection of endothelium. Detection of the tubuloreticular
bodies related to the virus in the endothelial cells sug-
gests dysfunctions developed in the capillary vessels lead
to clinical and pathological changes during the
disease. Furthermore, increase of the capillary permeabil-
ity and coagulation dysfunctions cause a tendency to
bleed21, 25, 26.
In this study, high serum levels of HS in the patients
with CCHF support efficiency of HS in the pathophysi-
ology of these events and accordingly disruption of the
vascular integrity. The levels of enzymes released by liver
and muscles (AST, ALT, LDH) remain higher in the pa-
tients with a severe course of the disease1.
Major markers of a poor prognosis of the disease re-
sulting in mortality compared to the other patients may
include a deep leukopenia and thrombocytopenia, high
levels of alanine aminotransferase and aspartate ami-
notransferase and prolongation of the partial thrombo-
plastin time4, 27–29. There was a strong same directional
correlation between the serum levels of HS and the levels
of ALP, ALT, AST, LDH and INR in the patients who
died from CCHF, although this was not found statisti-
cally significant since the number of the case was insuffi-
cient.
In conclusion, we believe HS values found high in
CCHF disease will clarify pathophysiology of the hem-
orrhagic findings. Further, comprehensive studies are
needed on this subject.
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